Effect of steroid treatment on the diagnostic yield of baseline 18f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma
Tóm tắt
Aggressive B cell lymphoma often requires prompt steroid treatment, even before baseline 18f-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) and definitive treatment, to alleviate symptoms or prevent organ damage. Since lymphoma is a steroid-sensitive malignancy, there are concerns that steroids might affect the results of FDG PET/CT and decrease its diagnostic yield. The aim of the current study was to evaluate the effect of steroids administered before baseline PET/CT on the maximum standardized uptake value (SUVmax) and additional PET/CT parameters. Retrospective review of the database in a tertiary medical center yielded 178 patients newly diagnosed with aggressive B cell lymphoma between January 2017 and May 2020 who had an available baseline FDG PET/CT scan. The cohort was divided into patients who received steroids before PET/CT (n = 47) and those who did not (n = 131), and the groups were compared for SUVmax and additional PET/CT parameters. The steroid-treated group had a higher disease stage and lactate dehydrogenase level compared to the steroid-naïve group, with a trend toward a higher international prognostic index. There was no significant between-group difference in SUVmax (P = 0.61). This finding remained consistent across steroid treatment durations and dosage regimens. Further evaluation revealed a significantly larger mean tumor volume and a trend toward a higher tumor metabolic burden in the steroid-treated group, yet no between-group difference in SUV mean or other PET/CT parameters. In this retrospective analysis of patients with aggressive B cell lymphoma, steroid prophase prior to baseline PET/CT did not decrease the diagnostic yield of the scan. However, further studies are required to fully appreciate the impact of steroids on PET CT parameters.
Tài liệu tham khảo
Kostakoglu L, Leonard JP, Kuji I, Coleman M, Vallabhajosula S, Goldsmith SJ. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma. Cancer. 2002;94(4):879–88. https://doi.org/10.1002/cncr.10336.
Verhoef G, et al. Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2002;13(9):1356–63. https://doi.org/10.1093/annonc/mdf256.
Salaün PY, et al. Good clinical practice recommendations for the use of PET/CT in oncology. Eur J Nucl Med Mol Imaging. 2020;47(1):28–50. https://doi.org/10.1007/s00259-019-04553-8.
Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer - A PET study. J Nucl Med. 1993;34(1):1–6.
Eskian M, et al. Effect of blood glucose level on standardized uptake value (SUV) in 18F- FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements. Eur J Nucl Med Mol Imaging. 2019;46(1):224–37. https://doi.org/10.1007/s00259-018-4194-x.
Sarikaya I, Sarikaya A, Sharma P. Assessing the effect of various blood glucose levels on 18F-FDG activity in the brain, liver, and blood pool. J Nucl Med Technol. 2019;47(4):313–8. https://doi.org/10.2967/JNMT.119.226969.
Zhao S, et al. Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions. Eur J Nucl Med. 2001;28(6):730–5. https://doi.org/10.1007/s002590100517.
Lamar ZS, et al. Hyperglycemia during first-line R-CHOP or dose adjusted R- EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration – a retrospective study. Leuk Lymphoma. 2018;59(8):1871–7. https://doi.org/10.1080/10428194.2017.1410889.Hyperglycemia.
Marić A, Miličević T, Lončar JV, Galušić D, Radman M. Patterns of glucose fluctuation are challenging in patients treated for non-Hodgkin’s lymphoma. Int J Gen Med. 2020;13:131–40. https://doi.org/10.2147/IJGM.S245779.
Imfeld S, et al. [18 F]FDG positron emission tomography in patients presenting with suspicion of giant cell arteritis-lessons froma vasculitis clinic. Eur Heart J Cardiovasc Imaging. 2018;19(8):933–40. https://doi.org/10.1093/ehjci/jex259.
Nielsen BD, Gormsen LC, Hansen IT, Keller KK, Therkildsen P, Hauge EM. Three days of high-dose glucocorticoid treatment attenuates large-vessel 18F-FDG uptake in large-vessel giant cell arteritis but with a limited impact on diagnostic accuracy. Eur J Nucl Med Mol Imaging. 2018;45(7):1119–28. https://doi.org/10.1007/s00259-018-4021-4.
Sehn LH, et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857–61. https://doi.org/10.1182/blood-2006-08-038257.
Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med. 1977;63(2):200–7. https://doi.org/10.1016/0002-9343(77)90233-9.
Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet. 2005;44(1):61–98. https://doi.org/10.2165/00003088-200544010-00003.
Boellaard R, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54. https://doi.org/10.1007/s00259-014-2961-x.
Taimen K, et al. The clinical impact of using 18 F-FDG-PET/CT in the diagnosis of suspected vasculitis: the effect of dose and timing of glucocorticoid treatment. Contrast Media Mol Imaging. 2019. https://doi.org/10.1155/2019/9157637.
Zhao S, et al. Effect of steroids on [f]fluorodeoxyglucose uptake in an experimental tumour model. Nucl Med Commun. 2004;25(7):727–30. https://doi.org/10.1097/01.mnm.0000126512.26835.27.
Nakajo M, et al. Dexamethasone suppression FDG PET/CT for differentiating between true-and false-positive pulmonary and mediastinal lymph node metastases in non-small cell lung cancer: a pilot study of FDG PET/CT after oral administration of dexamethasone. Radiology. 2016;279(1):246–53. https://doi.org/10.1148/radiol.2015150883.
Bertaux M, et al. Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study. J Neurooncol. 2020;148(2):343–52. https://doi.org/10.1007/s11060-020-03525-5.
Oh DY, et al. Does diabetes mellitus influence standardized uptake values of fluorodeoxyglucose positron emission tomography in colorectal cancer? Intest Res. 2014;12(2):146. https://doi.org/10.5217/ir.2014.12.2.146.
Gorenberg M, Hallett WA, O’Doherty MJ. Does diabetes affect [18F]FDG standardised uptake values in lung cancer? Eur J Nucl Med. 2002;29(10):1324–7. https://doi.org/10.1007/s00259-002-0887-1.
Sprinz C, et al. Effects of blood glucose level on 18F-FDG uptake for PET/CT in normal organs: a systematic review. PLoS ONE. 2018;13(2):8–19. https://doi.org/10.1371/journal.pone.0193140.
Rubello D, et al. Variability of hepatic 18F-FDG uptake at interim PET in patients with Hodgkin lymphoma. Clin Nucl Med. 2015;40(8):e405–10. https://doi.org/10.1097/RLU.0000000000000828.